Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Plasmodium vivax | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Chlamydia trachomatis | DNA ligase | 0.0012 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | FHA domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | NAD-dependent DNA ligase, Lig | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Mycobacterium ulcerans | NAD-dependent DNA ligase LigA | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Mycobacterium leprae | PROBABLE DNA LIGASE [NAD DEPENDENT] LIGA (POLYDEOXYRIBONUCLEOTIDE SYNTHASE [NAD+]) | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | Activator 1 140 kDa subunit, putative | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0 | 0.5 |
Treponema pallidum | DNA ligase (lig) | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Toxoplasma gondii | ATPase, AAA family protein | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | replication factor C large subunit, putative | 0.0012 | 0 | 0.5 |
Plasmodium falciparum | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Giardia lamblia | Replication factor C, subunit 1 | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.